FCGR3A
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Overview
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trastuzumab.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
- 1 · What it is
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
- 2 · What goes wrong in cancer
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG).
- 3 · How drugs use it
No product in this corpus aims at FCGR3A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:3619 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P08637 (protein name, function text, keywords and locations (REST API)); CIViC gene FCGR3A (2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0))
Biology
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC. Location: Cell membrane; Secreted (UniProt). Locus 1q23.3 (HGNC).
- Breast cancer: CIViC evidence names this disease
- HER2-positive breast cancer: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"FCGR3A" OR ABSTRACT:"FCGR3A" OR TITLE:"Fc gamma receptor IIIa" OR ABSTRACT:"Fc gamma receptor IIIa" OR TITLE:"Low affinity immunoglobulin gamma Fc region receptor III-A" OR ABSTRACT:"Low affinity immunoglobulin gamma Fc region receptor III-A" OR TITLE:"CD16" OR ABSTRACT:"CD16" OR TITLE:"CD16a" OR ABSTRACT:"CD16a" OR TITLE:"FcgammaRIIIa" OR ABSTRACT:"FcgammaRIIIa") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCGR3A, not a curated reading list.
Similar pages
not linked directly; found by shared links- TermFc engineering / effector function
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
- TreatmentMargetuximab
Shares NK-cell recognition: missing self & stress ligands, HER2-positive breast cancer.
- PathwayExtrinsic apoptosis (death receptors)
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
- TermADCC (antibody-dependent cellular cytotoxicity)
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
- TargetCD38
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.